Philadelphia PA– CancerLife, a leading provider of digital support and resources for cancer patients and their families, today announced a partnership with Eversana, a full-service commercial solutions provider for the life sciences industry, to apply for FDA Breakthrough status.
The partnership will leverage Eversana’s expertise in regulatory affairs and commercialization to support CancerLife’s mission of improving the lives of cancer patients by offering innovative and accessible digital solutions.
“At CancerLife, our goal is to empower patients and their families with the information and support they need to navigate their cancer journey,” said Charles Coltman, CEO of CancerLife. “By partnering with Eversana, we are taking a major step forward in our mission and bringing our innovative solutions to patients faster that meets the highest level of clinical validation on the market.”
Eversana will work with CancerLife to provide regulatory and commercial support for submitting their product for FDA Breakthrough status. The Breakthrough designation is a process for expediting the development and review of medical products that demonstrate the potential to substantially improve existing treatment.
“Eversana is proud to partner with CancerLife to support their mission and bring innovative solutions to patients in need,” said Martin Culjat, Head of Digital Health at Eversana. “Our expertise in regulatory affairs and commercialization, combined with CancerLife’s innovative digital platform, will help bring life-changing solutions to patients faster.”
About CancerLife
CancerLife is a leading provider of digital support and resources for cancer patients and their families. Our cancer support platform is validated to raise Quality of Life. Their mission is to empower patients and families with the information and support they need to navigate their cancer journey.
About Eversana
Eversana is a full-service commercial solutions provider for the life sciences industry, offering a range of services, including regulatory affairs, commercialization, and market access. Eversana’s mission is to bring innovative solutions to patients faster, by supporting life sciences companies in their efforts to bring new treatments to market.
Transcription of video:
Hi, Charlie Coltman here, founder and CEO of Cancer Life. Today’s announcement is that we have some exciting news Our clinical trial data, which we presented at the San Antonio Breast Cancer Symposium in December. I’ve been taking those results and you know, passing them around to some industry experts. And today we’re announcing that we are partnering with Eversana a 400 million life sciences consulting firm, and Mar Martin Culjick, who runs their digital health team, who took a look at our results, who was blown away by our expertise in improving quality of life for cancer patients, looking at the clinical trial design, looking at the results across 117 different area codes, which was really significant because as we know that disparities of care across cancer continue care continuum is a huge problem. But we raise quality of life by 14.2% from the EQ five VAs scores which is a self-reported score, as well as a 9.9 improvement on the index score. So both
Of those numbers contained in the EQ five were improved. So we are going through breakthrough status, which is exciting. We believe that digital medicine or digital therapeutics are the, is the next wave of digital health
As you go through treatment, you’ll be, you know, prescribed a treatment regimen in terms of pharmaceutical treatment, but also you’ll be given a companion app. And cancer life can improve quality of life by cor collecting the right data that you can physically share with your care team as well as get the social support that you need during treatment. And both of those things improves physical functioning because we were able to reduce the symptom burden of each patient by 78%, as well as the social support you and emotional support you get, which improves mental health for patients as they go through the journey. So exciting news to partner with Eversana and looking forward to, to applying for that breakthrough status and announcing that probably in the next 60 days. Anyway. Thank you friends.